权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigation of endomucin as a novel regulator of angiogenesis

内粘蛋白作为血管生成的新型调节剂的研究

基本信息

批准号：
10456724
负责人：
Patricia Ann D'Amore
金额：
$ 50.05万
依托单位：
SCHEPENS EYE RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-02-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10456724
关键词：
Adult Age related macular degeneration Antigens Binding Binding Proteins Biochemical Biological Blood Vessels Blood capillaries Capillary Endothelial Cell Cells Characteristics Choroidal Neovascularization Chronic Combined Modality Therapy Data Development Dimerization Disease Endocytosis Endothelial Cells Endothelium Extracellular Domain Glycocalyx Glycoproteins Growth Human Immune Sera Immunoprecipitation In Vitro Investigation KDR gene Knock-out Lasers Lead Ligand Binding Ligands LoxP-flanked allele Mass Spectrum Analysis Mediating Methods Modeling Molecular Monoclonal Antibodies Mus Mutagenesis N-Glycosylation Site Ocular Pathology Pathologic Pathologic Neovascularization Pathology Patients Permeability Pinocytosis Process Reagent Receptor Activation Receptor Signaling Regulation Reporting Retina Role Route Signal Pathway Signal Transduction Site Small Interfering RNA Structure Surface Tamoxifen Testing Tube Vascular Endothelial Cell Vascular Endothelial Growth Factors Vascular Permeabilities Vascularization Work angiogenesis bevacizumab cadherin 5 cell motility endothelial-specific sialomucin genetic approach glycosylation in vivo inhibitor insight knock-down migration mouse model mutant neovascularization new growth novel prevent vascular factor

项目摘要

Project Summary We have identified endomucin (EMCN), a component of the endothelial cell (EC) glycocalyx, to be a novel regulator of VEGFR2 signaling. siRNA-mediated knockdown of EMCN in human retinal capillary EC blocks VEGF-induced angiogenic functions (proliferation, migration, and tube formation) in vitro and neovascularization in vivo. Our data indicate that EMCN is necessary for VEGF-stimulated VEGFR2 internalization. We hypothesize that EMCN regulates VEGF-induced VEGFR2 endocytosis, and thus VEGF signaling in EC. We propose: (i) To use a genetic approach to examine the role of EMCN in developmental angiogenesis and pathologic neovascularization as well as in adult vascular stability. We have generated mice with floxed EMCN that will be bred with Rosa-Cre to assess the effect of total EMCN knockout, and with tamoxifen-inducible VE-cadherin to examine EC-specific knockout. (ii) To elucidate the molecular mechanism through which EMCN regulates VEGFR2 internalization and signaling, cell biological and biochemical methods will be employed to determine how EMCN functions in VEGF-VEGFR2 endocytosis, to elucidate the structural characteristics of EMCN necessary for its role in VEGFR2 endocytosis, and to identify EMCN-VEGFR2 binding proteins that may be involved in VEGFR2 internalization. (iii) To develop a monoclonal antibody that interferes with the association between EMCN and VEGFR2, the glycosylated extracellular domain of EMCN will be used as an antigen. Our preliminary data using truncation mutants of EMCN indicate that the extracellular domain of EMCN is necessary for its effect on VEGFR2 signaling. Antisera will be screened on the basis of its effects on VEGF-induced EC migration and VEGFR2 internalization. Antisera, that we have shown to interfere with the effect of EMCN on VEGF-induced migration and VEGFR2 internalization, will be tested for its the ability to block pathologic VEGF-induced permeability and angiogenesis in vivo – alone, compared to aflibercept (VEGF trap), or as a combination therapy with aflibercept. VEGF neutralization is the primary mode of treatment for a number of ocular pathologies that involve neovascularization and vessel permeability. While remarkably successful, there is a significant proportion of patients who appear unresponsive to anti-VEGF therapy. In addition, a number of non-vascular cells in the retina express VEGFR2, and are thus vulnerable to chronic neutralization of local VEGF, with implications for neurotrophic and survival functions. Results of these studies will provide new information about the role of EMCN in vascular development, vascular integrity, and pathologic vessel growth; will reveal novel insights into the regulation of VEGF-stimulated VEGFR2 signaling; and, will test EMCN as a unique endothelial cell-specific target for blocking abnormal VEGF-induced angiogenesis and vascular permeability. !

项目总结